A carregar...
Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy
Paclitaxel has been shown to have clinical activity in the treatment of small cell lung cancer (SCLC). However, its role as third-line chemotherapy for SCLC after both etoposide- and camptothecin-based regimens has not been clarified. All patients with refractory SCLC who were treated with paclitaxe...
Na minha lista:
| Publicado no: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5662365/ https://ncbi.nlm.nih.gov/pubmed/29049199 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000008176 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|